Under white bagging, a specialty pharmacy — not the practice — purchases and owns the drug, then ships a patient-specific, pre-labeled dose to the practice for administration. Because the practice never bought the drug, it cannot bill the drug's HCPCS J-code on the medical claim; it bills only the administration CPT code. The drug's cost, and any margin between acquisition and reimbursement, moves entirely to the dispensing specialty pharmacy's pharmacy-benefit claim. That single change — one claim line instead of two — is the entire practical difference this page is built around; the definitional side of white bagging is well covered elsewhere and isn't repeated here in depth.
White bagging is when a specialty pharmacy dispenses a specialty drug to a healthcare provider or facility for a specific, named patient rather than to the patient directly. The pharmacy owns and ships the drug; the practice administers it and bills only the administration code. Brown bagging is the patient-facing variant: the specialty pharmacy dispenses the drug to the patient (or caregiver), who then carries it to the practice for administration — many payers and hospital pharmacy departments discourage or outright prohibit brown bagging for cold-chain and chain-of-custody reasons. Gold bagging is a newer, less standardized term for a health system's own affiliated or "captive" specialty pharmacy handling prescribing, dispensing, and administration internally — functionally similar to white bagging, but the pharmacy-side revenue stays inside the health system rather than going to an external specialty pharmacy. Buy-and-bill, covered in full on its own pillar page, is the baseline all three bagging models are compared against: the practice purchases the drug itself, administers it, and bills both the drug's J-code and the administration CPT code on the same claim.
This site's buy-and-bill worked examples bind to the CMS Q2 2026 Average Sales Price file across 417 specialty and infusion drugs in the CareCost drug library; the revenue comparison below uses that same live data-asp pricing to show exactly what a white-bagging arrangement removes from a practice's claim.
Every billing consequence of white bagging traces back to one fact: the practice never purchases the drug. Everything else on this page follows from that.
This is the source of the coordination problem infusion practices raise most often about white bagging: the specialty pharmacy ships an exact, patient-labeled quantity based on the dose ordered at the time the prescription was written, but the practice may need to adjust the dose at the time of administration — a weight change, a dose-reduction protocol step, a clinical judgment call. Under buy-and-bill, the practice draws whatever it needs from its own vial stock and reports the difference as JW. Under white bagging, there is no vial stock to draw from and no JW line to report a mismatch — a shipped unit that doesn't match the administered dose is either wasted at the pharmacy's cost, a delay while a corrected shipment is requested, or (in the least defensible outcome) a dose given at whatever quantity actually arrived.
For the full four-stage buy-and-bill claim lifecycle and the ASP+6% reimbursement mechanics it depends on, see the buy-and-bill pillar page.
White bagging mandates are payer- and plan-specific, not a universal rule. The general pattern industry advocacy and policy groups describe: some commercial payers and PBM-affiliated specialty pharmacies require white bagging for a defined list of high-cost infused specialty drugs as a cost-management tactic, typically applied per drug and per plan rather than across a practice's entire formulary. Medicare fee-for-service does not mandate white bagging. Whether a given payer requires it for a given drug is a policy question to confirm directly with that payer — treat any mandate as plan-specific until verified, not as a blanket rule.
Remicade (J1745) is a representative example because infliximab infusions are among the specialty drugs most commonly routed through white-bagging arrangements by commercial payers. The dose below is a standard 5 mg/kg maintenance infusion for a 72 kg adult — 360 mg, billed as 36 units of J1745 (1 unit = 10 mg), administered over 2+ hours under non-chemo infusion codes 96365 + 96366.
Under white bagging, a specialty pharmacy purchases and owns the drug, then ships a patient-specific, pre-labeled dose to the practice for administration. Because the practice never purchased the drug, it does not bill the drug's HCPCS J-code or Q-code on the medical claim — it bills only the administration CPT code (an infusion or injection code). The drug itself is billed separately by the specialty pharmacy under the patient's pharmacy benefit, using the National Drug Code (NDC), not the medical claim the practice submits.
No, not on the practice's claim. JW and JZ report discarded and zero-discarded drug on the HCPCS J-code line for a single-dose container (CMS IOM Pub 100-04, Ch. 17, §40) — they attach to the drug line itself. Under white bagging the practice submits no J-code line at all, since it never purchased the drug and bills only the administration CPT code, so there is no drug line for JW or JZ to attach to. Any waste from the shipped unit is a dispensing-pharmacy billing question under its own pharmacy claim, not something the administering practice reports.
All three route a drug through a pharmacy rather than the practice's own purchased inventory, but differ in who touches the drug in between. White bagging: a specialty pharmacy ships a patient-specific dose directly to the practice for administration. Brown bagging: the specialty pharmacy dispenses the drug to the patient, who then carries it to the practice — many payers and hospitals discourage or prohibit this for cold-chain and chain-of-custody reasons. Gold bagging: a health system's own affiliated specialty pharmacy handles prescribing, dispensing, and administration internally, keeping the pharmacy-side economics inside the health system instead of ceding them to an external specialty pharmacy.
Under buy-and-bill, the practice's claim carries two revenue lines: the drug (paid at the ASP-based payment limit, which includes the margin between acquisition cost and reimbursement) and the administration CPT code. Under white bagging, the practice's claim carries only the administration CPT line — the drug-line revenue and any acquisition-to-reimbursement spread goes to the specialty pharmacy instead, because the practice never bought the drug. The administration reimbursement itself is typically unchanged; what disappears is the drug-margin line entirely.
No. White bagging mandates are payer- and plan-specific, and typically apply to a defined list of high-cost specialty drugs rather than a practice's entire formulary. Some commercial payers and PBM-affiliated specialty pharmacies mandate white bagging for select infused biologics as a cost-management tactic; Medicare fee-for-service does not mandate white bagging. Confirm mandate status per payer, per plan, and per drug — do not assume a policy applies without checking the specific payer's current medical or pharmacy policy.
Sometimes. A growing number of states have passed laws restricting or prohibiting payer-mandated white or brown bagging for certain drug classes, particularly oncology infusions, in response to provider advocacy over dosing flexibility, shipping delays, and lost drug-margin revenue. Where no state law applies, practices can request a payer-specific exception (commonly framed around dose-timing flexibility, cold-chain risk, or clinical urgency), but the outcome is plan-specific and not guaranteed — check your state's current law and the payer's exception process before assuming either path is available.
data-asp bindings read from.All sources are publicly available federal publications, industry glossaries, or trade/advocacy-group publications, cited by name rather than paraphrased as unnamed "industry sources." The methodology by which we resolve source disagreements is described in the Methodology.